Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

The traditional view holds that apoptosis is non-immunogenic and does not induce an
inflammatory response. However, recent studies have suggested that certain …

Assessment of measurable residual disease (often referred to as “minimal residual disease”)
has emerged as a highly sensitive indicator of disease burden during and at the end of …

Minimal residual disease (MRD) negativity, defined as< 1 chronic lymphocytic leukemia
(CLL) cell detectable per 10 000 leukocytes, has been shown to independently predict for …

The high complete remission rate with first-line combined fludarabine, cyclophosphamide,
and rituximab (FCR) begs the question of the value of minimal residual disease (MRD) …

Deep remission and prolonged disease-free survival can be achieved with first-line
chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and …

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual
disease (MRD) monitoring, due to the availability of drug combinations capable of …